Literature DB >> 22285911

ABC transporters and their role in nucleoside and nucleotide drug resistance.

Yu Fukuda1, John D Schuetz.   

Abstract

ATP-binding cassette (ABC) transporters confer drug resistance against a wide range of chemotherapeutic agents, including nucleoside and nucleotide based drugs. While nucleoside based drugs have been used for many years in the treatment of solid and hematological malignancies as well as viral and autoimmune diseases, the potential contribution of ABC transporters has only recently been recognized. This neglect is likely because activation of nucleoside derivatives require an initial carrier-mediated uptake step followed by phosphorylation by nucleoside kinases, and defects in uptake or kinase activation were considered the primary mechanisms of nucleoside drug resistance. However, recent studies demonstrate that members of the ABCC transporter subfamily reduce the intracellular concentration of monophosphorylated nucleoside drugs. In addition to the ABCC subfamily members, ABCG2 has been shown to transport nucleoside drugs and nucleoside-monophosphate derivatives of clinically relevant nucleoside drugs such as cytarabine, cladribine, and clofarabine to name a few. This review will discuss ABC transporters and how they interact with other processes affecting the efficacy of nucleoside based drugs. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285911      PMCID: PMC3319017          DOI: 10.1016/j.bcp.2011.12.042

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  127 in total

1.  Structure of a bacterial multidrug ABC transporter.

Authors:  Roger J P Dawson; Kaspar P Locher
Journal:  Nature       Date:  2006-08-30       Impact factor: 49.962

Review 2.  High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.

Authors:  Wolfgang Kern; Elihu H Estey
Journal:  Cancer       Date:  2006-07-01       Impact factor: 6.860

3.  The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.

Authors:  Tetsuya Oguri; Hiroyuki Achiwa; Shigeki Sato; Yuji Bessho; Yuko Takano; Mikinori Miyazaki; Hideki Muramatsu; Hiroyoshi Maeda; Takashi Niimi; Ryuzo Ueda
Journal:  Mol Cancer Ther       Date:  2006-07       Impact factor: 6.261

4.  Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides.

Authors:  T W Loo; D M Clarke
Journal:  J Biol Chem       Date:  1994-03-11       Impact factor: 5.157

5.  Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1).

Authors:  Su-Ryang Kim; Yoshiro Saito; Keiko Maekawa; Emiko Sugiyama; Nahoko Kaniwa; Hideki Ueno; Takuji Okusaka; Chigusa Morizane; Noboru Yamamoto; Masafumi Ikeda; Teruhiko Yoshida; Hironobu Minami; Junji Furuse; Hiroshi Ishii; Nagahiro Saijo; Naoyuki Kamatani; Shogo Ozawa; Jun-ichi Sawada
Journal:  Drug Metab Pharmacokinet       Date:  2006-06       Impact factor: 3.614

6.  Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.

Authors:  Carla S Wilson; George S Davidson; Shawn B Martin; Erik Andries; Jeffrey Potter; Richard Harvey; Kerem Ar; Yuexian Xu; Kenneth J Kopecky; Donna P Ankerst; Holly Gundacker; Marilyn L Slovak; Monica Mosquera-Caro; I-Ming Chen; Derek L Stirewalt; Maurice Murphy; Frederick A Schultz; Huining Kang; Xuefei Wang; Jerald P Radich; Frederick R Appelbaum; Susan R Atlas; John Godwin; Cheryl L Willman
Journal:  Blood       Date:  2006-04-04       Impact factor: 22.113

7.  Membrane topology of the transporter associated with antigen processing (TAP1) within an assembled functional peptide-loading complex.

Authors:  Susanne Schrodt; Joachim Koch; Robert Tampé
Journal:  J Biol Chem       Date:  2006-01-05       Impact factor: 5.157

8.  A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent.

Authors:  B L Robbins; M C Connelly; D R Marshall; R V Srinivas; A Fridland
Journal:  Mol Pharmacol       Date:  1995-02       Impact factor: 4.436

9.  2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines.

Authors:  V W Ruiz van Haperen; G Veerman; J B Vermorken; G J Peters
Journal:  Biochem Pharmacol       Date:  1993-08-17       Impact factor: 5.858

10.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

Authors:  A H Schinkel; J J Smit; O van Tellingen; J H Beijnen; E Wagenaar; L van Deemter; C A Mol; M A van der Valk; E C Robanus-Maandag; H P te Riele
Journal:  Cell       Date:  1994-05-20       Impact factor: 41.582

View more
  54 in total

Review 1.  Drug transporters in the central nervous system.

Authors:  Bruno Stieger; Bo Gao
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

Review 2.  Dependence of Leishmania parasite on host derived ATP: an overview of extracellular nucleotide metabolism in parasite.

Authors:  Kashika Arora; Ambak Kumar Rai
Journal:  J Parasit Dis       Date:  2018-12-01

3.  Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia.

Authors:  David G J Cucchi; Costa Bachas; Marry M van den Heuvel-Eibrink; Susan T C J M Arentsen-Peters; Zinia J Kwidama; Gerrit J Schuurhuis; Yehuda G Assaraf; Valérie de Haas; Gertjan J L Kaspers; Jacqueline Cloos
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

Review 4.  Nanoformulations for combination or cascade anticancer therapy.

Authors:  Lei Miao; Shutao Guo; C Michael Lin; Qi Liu; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

5.  Phase-II metabolism limits the antiproliferative activity of urolithins in human colon cancer cells.

Authors:  Antonio González-Sarrías; Juan Antonio Giménez-Bastida; María Ángeles Núñez-Sánchez; Mar Larrosa; María Teresa García-Conesa; Francisco A Tomás-Barberán; Juan Carlos Espín
Journal:  Eur J Nutr       Date:  2014-04       Impact factor: 5.614

6.  Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.

Authors:  Isabelle Laverdière; Chantal Guillemette; Ryad Tamouza; Pascale Loiseau; Regis Peffault de Latour; Marie Robin; Félix Couture; Alain Filion; Marc Lalancette; Alan Tourancheau; Dominique Charron; Gérard Socié; Éric Lévesque
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

Review 7.  Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking.

Authors:  Xue Xue; Matthew D Hall; Qiang Zhang; Paul C Wang; Michael M Gottesman; Xing-Jie Liang
Journal:  ACS Nano       Date:  2013-12-10       Impact factor: 15.881

8.  ABCG2 requires a single aromatic amino acid to "clamp" substrates and inhibitors into the binding pocket.

Authors:  Tomoka Gose; Talha Shafi; Yu Fukuda; Sourav Das; Yao Wang; Alice Allcock; Ailsa Gavan McHarg; John Lynch; Taosheng Chen; Ikumi Tamai; Anang Shelat; Robert C Ford; John D Schuetz
Journal:  FASEB J       Date:  2020-02-17       Impact factor: 5.191

9.  Comparative transcriptomes and reciprocal best hit analysis revealed potential pigment genes in two color forms of Tetranychus urticae.

Authors:  Yi-Dan Mo; Si-Xia Yang; Jing-Yu Zhao; Peng-Yu Jin; Xiao-Yue Hong
Journal:  Exp Appl Acarol       Date:  2017-11-07       Impact factor: 2.132

10.  Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity.

Authors:  Yu Fukuda; Kazumasa Takenaka; Alex Sparreboom; Satish B Cheepala; Chung-Pu Wu; Sean Ekins; Suresh V Ambudkar; John D Schuetz
Journal:  Mol Pharmacol       Date:  2013-06-17       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.